MAPT and Alzheimer disease: PBM not only enhances memory in AD model mice (Meng et al., 2013; Tao et al., 2021; Grillo et al., 2013) but also shows promise in reducing Aβ burden and phosphorylated tau protein levels in plasma (De Taboada et al., 2011), cerebrospinal fluid (De Taboada et al., 2011), and the brain (Purushothuman et al., 2015), highlighting its significant therapeutic potential for AD.